BSX Boston Scientific Corp
Price (delayed)
$101.17
Market cap
$149.3B
P/E Ratio
80.29
Dividend/share
N/A
EPS
$1.26
Enterprise value
$159.64B
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology,
Highlights
The revenue has increased by 18% YoY and by 5% from the previous quarter
The EPS has increased by 17% YoY and by 3.3% from the previous quarter
The P/E is 17% above the last 4 quarters average of 64.7 but 5% below the 5-year quarterly average of 79.8
BSX's quick ratio is down by 46% since the previous quarter and by 27% year-on-year
Boston Scientific's debt has increased by 18% YoY
Key stats
What are the main financial stats of BSX
Market
Valuations
Earnings
Shares outstanding
1.48B
Market cap
$149.3B
Enterprise value
$159.64B
Price to earnings (P/E)
80.29
Price to book (P/B)
6.85
Price to sales (P/S)
8.89
EV/EBIT
61.52
EV/EBITDA
41.31
EV/Sales
9.53
Revenue
$16.75B
Gross profit
$11.49B
Operating income
$2.61B
Net income
$1.85B
EBIT
$2.6B
EBITDA
$3.86B
Free cash flow
$2.67B
Per share
Balance sheet
Liquidity
EPS
$1.26
EPS diluted
$1.25
Free cash flow per share
$1.81
Book value per share
$14.77
Revenue per share
$11.38
TBVPS
$10.62
Total assets
$39.4B
Total liabilities
$17.39B
Debt
$10.75B
Equity
$21.77B
Working capital
$521M
Debt to equity
0.49
Current ratio
1.08
Quick ratio
0.46
Net debt/EBITDA
2.67
Margins
Efficiency
Dividend
EBITDA margin
23.1%
Gross margin
68.6%
Net margin
11.1%
Operating margin
15.6%
Return on assets
4.9%
Return on equity
9%
Return on invested capital
13.2%
Return on capital employed
7.9%
Return on sales
15.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BSX stock price
How has the Boston Scientific stock price performed over time
Intraday
6.44%
1 week
6.22%
1 month
0.48%
1 year
46.64%
YTD
13.27%
QTD
0.29%
Financial performance
How have Boston Scientific's revenue and profit performed over time
Revenue
$16.75B
Gross profit
$11.49B
Operating income
$2.61B
Net income
$1.85B
Gross margin
68.6%
Net margin
11.1%
The revenue has increased by 18% YoY and by 5% from the previous quarter
Boston Scientific's net income has increased by 16% YoY and by 3.5% QoQ
Boston Scientific's gross profit has increased by 16% YoY and by 4.7% QoQ
Boston Scientific's operating income has increased by 11% YoY and by 3.8% from the previous quarter
Growth
What is Boston Scientific's growth rate over time
Valuation
What is Boston Scientific stock price valuation
P/E
80.29
P/B
6.85
P/S
8.89
EV/EBIT
61.52
EV/EBITDA
41.31
EV/Sales
9.53
The P/E is 17% above the last 4 quarters average of 64.7 but 5% below the 5-year quarterly average of 79.8
The EPS has increased by 17% YoY and by 3.3% from the previous quarter
The stock's price to book (P/B) is 57% more than its 5-year quarterly average of 4.1 and 13% more than its last 4 quarters average of 5.7
The equity has grown by 13% YoY and by 5% from the previous quarter
BSX's P/S is 46% above its 5-year quarterly average of 5.7 and 11% above its last 4 quarters average of 7.5
The revenue has increased by 18% YoY and by 5% from the previous quarter
Efficiency
How efficient is Boston Scientific business performance
The return on assets has grown by 7% year-on-year
The return on equity has increased by 6% year-on-year
BSX's ROIC is up by 6% YoY
Dividends
What is BSX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BSX.
Financial health
How did Boston Scientific financials performed over time
Boston Scientific's total assets is 127% more than its total liabilities
BSX's quick ratio is down by 46% since the previous quarter and by 27% year-on-year
BSX's current ratio is down by 27% since the previous quarter and by 18% year-on-year
Boston Scientific's debt is 51% lower than its equity
Boston Scientific's debt has increased by 18% YoY
The equity has grown by 13% YoY and by 5% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.